Inhibitors of disease-promoting activities of senescence

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AG029023-01
Agency Tracking Number: AG029023
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2006
Solicitation Year: 2006
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Small Business Information
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (518) 641-6486
Business Contact
Phone: (518) 641-6486
Research Institution
DESCRIPTION (provided by applicant): The proposed project is aimed at developing a novel class of drugs against chronic diseases associated with old age. Such agents act by inhibiting a newly discovered regulatory pathway that endows senescent cells with disease- promoting paracrine activities. Senescent cells, which arise as a result of aging or stress response, have been found to secrete multiple proteins implicated in age-related diseases, including Alzheimer's disease, amyloidosis, atherosclerosis, chronic renal disease, arthritis and cancer. These proteins are upregulated in response to the expression of cyclin-dependent kinase inhibitor (CDKI) proteins, which mediate cell cycle arrest in senescence and other physiological situations. High-throughput screening, followed by a battery of biological assays, resulted in the identification of several related compounds that inhibit disease-promoting activities of senescent cells. These molecules, designated SNX2-class compounds, do not interfere with the essential role of CDKI in cell cycle arrest, but they block the induction of disease-associated genes in CDKI-arrested cells. These compounds also block the development of senescent morphology in drug-damaged fibroblasts and inhibit the secretion of anti-apoptotic factors by CDKI-expressing cells. SNX2-class compounds may be considered as prototype drugs against the disease-promoting effects of cell senescence. The molecular target of SNX2-class compounds is presently unknown. Its identification is essential both for understanding the mechanism of action and for lead optimization of SNX2-class compounds. The goal of this Phase I SBIR is to identify the most likely molecular target of SNX2-class compounds. Aim 1 of the proposed strategy is based on the selection of proteins, increased expression of which is associated with phenotypic resistance to SNX2- class compounds. Aim 2 is to identify signal transduction pathways affected by the compounds, by determining the effect of the compounds on cellular protein kinase and gene expression profiles. Proteins identified in Aim 1 and key regulators of signal transduction pathways identified in Aim 2 will then be screened by RNAi knockdown, to determine which of these proteins are required for the induction of transcription by CDKI. A protein with such properties will represent the most likely molecular target of SNX2-class compounds. Its identification should facilitate the development and optimization of new drugs for the chemoprevention or therapy of age-related diseases. With the aging of the American population, chronic age-related diseases, such as Alzheimer's disease, atherosclerosis, chronic renal disease and cancer, are becoming an increasingly greater burden on the society. There is a great need for developing novel pharmaceuticals that would be efficient against these largely incurable diseases. Senex Biotechnology, Inc. is a startup drug discovery company that targets a newly discovered biological regulatory pathway, which causes increased production of proteins implicated in different age-related diseases. Senex has discovered drug-like small molecules that block this disease-promoting pathway. The goal of this Phase I SBIR application is to identify the molecular target of these novel compounds. Such identification should make it possible to develop a new type of drugs that will slow down or reverse the development of Alzheimer's disease or other age-related diseases.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government